Increased plasma levels of galectin-1 in pancreatic cancer : potential use as biomarker
Martinez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques)
Barranco, Luis E. (Institut Hospital del Mar d'Investigacions Mèdiques)
Orozco, Carlos A. (Institut Hospital del Mar d'Investigacions Mèdiques)
Moreno, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques)
Visa, Laura (Hospital del Mar (Barcelona, Catalunya))
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
Oldfield, Lucy (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK)
Neoptolemos, John P. (Department of General Surgery, University of Heidelberg, Heidelberg, Germany)
Greenhalf, William (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK)
Earl, Julie (Hospital Universitario Ramón y Cajal (Madrid))
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid))
Costello, Eithne (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK)
Navarro, Pilar (Institut d'Investigació Biomèdica Sant Pau)

Data:	2018
Resum:	Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
Ajuts:	Ministerio de Economía y Competitividad ISCIII/FEDER/PI14-00125 Ministerio de Economía y Competitividad ISCIII/FEDER/PI17-00199 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR-143 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-255 Instituto de Salud Carlos III PI15-02101 Instituto de Salud Carlos III FEDER/PT17-0015-0011
Nota:	Altres ajuts: This work was supported by grants from the Spanish Ministerio de Economía y Competitividad/ISCIII-FEDER, the Carmen Delgado/Miguel Pérez-Mateo AESPANC-ACANPAN 2016 grant and the "Generalitat de Catalunya" to P.N., , EU TRANSCAN AC14/00033 and AECC grants to A.C., and grants from Instituto de Salud Carlos III/FEDER and the "Xarxa de Bancs de tumors" sponsored by Pla Director d'Oncologia de Catalunya (XBTC). CAO received funding from the International PhD studies Fellowship "Créditos Beca Francisco José de Caldas" n° 529-2011 Colciencias, Colombia.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Galectin-1 ; Pancreatic cancer ; Chronic pancreatitis ; Biomarker
Publicat a:	Oncotarget, Vol. 9 (august 2018) , p. 32984-32996, ISSN 1949-2553

DOI: 10.18632/oncotarget.26034
PMID: 30250644

13 p, 2.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats